page_banner

Products

FADCP CAS: 171887-03-9

Short Description:

Catalog Number: XD94107
Cas: 171887-03-9
Molecular Formula: C5H4Cl2N4O
Molecular Weight: 207.02
Availability: In Stock 
Price:  
Prepack:  
Bulk Pack: Request Quote

Product Detail

Product Tags

Catalog Number XD94107
Product Name FADCP
CAS 171887-03-9
Molecular Formula C5H4Cl2N4O
Molecular Weight 207.02
Storage Details Ambient

 

Product Specification

Appearance White powder
Assay 99% min

 

Abacavir (ABV) is a nucleoside reverse transcriptase inhibitor (NRTI) that is commonly used in the treatment of HIV infection and AIDS. It belongs to the class of antiretroviral drugs and is an essential component of combination therapy regimens. This medication is marketed under various brand names, including Ziagen.The primary pharmacological action of Abacavir is the inhibition of reverse transcriptase, an enzyme that is crucial for the replication of the HIV virus. By blocking this enzyme, Abacavir prevents the replication and spread of the virus within the body, thus helping to control HIV infection and slow the progression of AIDS.Abacavir is usually prescribed in combination with other antiretroviral drugs, forming what is known as highly active antiretroviral therapy (HAART). This approach, which involves a combination of drugs with different mechanisms of action, helps to suppress viral replication and reduce the risk of developing drug resistance.One of the notable advantages of Abacavir is its high potency and effectiveness against HIV. It has demonstrated strong antiviral activity, reducing the viral load and boosting CD4+ T-cell counts. CD4+ T-cells play a crucial role in immune function, and HIV targets and destroys these cells. By preserving and increasing CD4+ T-cell counts, Abacavir helps to maintain a functioning immune system, improving overall health outcomes in individuals with HIV/AIDS.In addition to its antiviral properties, Abacavir has a good safety profile and is generally well-tolerated by patients. However, it's important to note that some individuals may experience adverse reactions, with the most severe being hypersensitivity reactions. It is crucial for patients to be screened for a specific genetic marker (HLA-B*5701) prior to initiating Abacavir therapy, as individuals positive for this marker are at an increased risk of developing hypersensitivity reactions.Abacavir is available in various forms, including tablets and oral solutions, providing flexibility in dosing and administration. The recommended dosage depends on a variety of factors, such as the patient's weight, co-morbidities, and other drugs they may be taking.Overall, Abacavir is a vital component of HIV/AIDS treatment and has significantly improved the prognosis and quality of life for individuals living with the disease. Its potent antiviral activity, compatibility with combination therapy, and relatively good safety profile make it an indispensable tool in the battle against HIV infection. However, as with any medication, it should only be used under the guidance and supervision of a healthcare professional.


  • Previous:
  • Next:

  • Close

    FADCP CAS: 171887-03-9